- Home
- NMCO vs ARCT Comparison
NMCO vs ARCT Comparison
Compare NMCO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- ARCT
- Stock Information
- Founded
- NMCO 2019
- ARCT 2013
- Country
- NMCO United States
- ARCT United States
- Employees
- NMCO N/A
- ARCT N/A
- Industry
- NMCO Finance/Investors Services
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- NMCO Finance
- ARCT Health Care
- Exchange
- NMCO Nasdaq
- ARCT Nasdaq
- Market Cap
- NMCO 611.9M
- ARCT 487.0M
- IPO Year
- NMCO N/A
- ARCT N/A
- Fundamental
- Price
- NMCO $10.87
- ARCT $16.74
- Analyst Decision
- NMCO
- ARCT Strong Buy
- Analyst Count
- NMCO 0
- ARCT 7
- Target Price
- NMCO N/A
- ARCT $65.00
- AVG Volume (30 Days)
- NMCO 207.6K
- ARCT 388.1K
- Earning Date
- NMCO 01-01-0001
- ARCT 03-06-2025
- Dividend Yield
- NMCO 5.43%
- ARCT N/A
- EPS Growth
- NMCO N/A
- ARCT N/A
- EPS
- NMCO N/A
- ARCT N/A
- Revenue
- NMCO N/A
- ARCT $160,399,000.00
- Revenue This Year
- NMCO N/A
- ARCT $7.33
- Revenue Next Year
- NMCO N/A
- ARCT $4.71
- P/E Ratio
- NMCO N/A
- ARCT N/A
- Revenue Growth
- NMCO N/A
- ARCT N/A
- 52 Week Low
- NMCO $8.52
- ARCT $14.30
- 52 Week High
- NMCO $11.64
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- NMCO 57.07
- ARCT 46.33
- Support Level
- NMCO $10.60
- ARCT $16.07
- Resistance Level
- NMCO $10.82
- ARCT $17.51
- Average True Range (ATR)
- NMCO 0.12
- ARCT 1.44
- MACD
- NMCO 0.04
- ARCT -0.11
- Stochastic Oscillator
- NMCO 95.12
- ARCT 15.43
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.